Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 1184 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Udenafil for congenital heart disease in adolescents after fontan palliation	Udenafil (Zydena; DA8159; ME-3113; WC-3043; WC-3055)	Congenital heart disease	Cardiovascular System	2018	View \| Download
Ublituximab in Combination with Ibrutinib for High Risk Chronic Lymphocytic Leukaemia	Ibrutinib (Imbruvica) , Ublituximab (TG-1101; LFB-R603)	Chronic lymphocytic leukaemia (CLL)	Haematological Cancer and Lymphomas	2018	View \| Download
Ublituximab for treating multiple sclerosis	Ublituximab (TG-1101; LFB-R603)	Multiple sclerosis (MS)	Neurology	2022	View \| Download
Ublituximab (TG-1101) in combination with umbralisib (TGR-1202) for chronic lymphocytic leukaemia	Ublituximab (TG-1101; LFB-R603) , Umbralisib (TGR-1202; RP-5264)	Chronic lymphocytic leukaemia (CLL)	Haematological Cancer and Lymphomas	2017	View \| Download
Tusamitamab Ravtansine for previously treated advanced Non-Small-Cell Lung Cancer	Tusamitamab ravtansine (SAR408701)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2021	View \| Download
Tucatinib with trastuzumab for treating colorectal cancer	Trastuzumab (Herceptin; RG-597) , Tucatinib (ONT-380)	Colorectal cancer	Gastrointestinal Cancer	2022	View \| Download
Tucatinib with trastuzumab emtansine for treating unresectable, locally advanced or metastatic HER2 positive breast cancer	Trastuzumab Emtansine (Kadcyla; T-DM1; PRO132365) , Tucatinib (ONT-380)	Breast cancer	Breast Cancer	2022	View \| Download
Tucatinib with trastuzumab and pertuzumab for maintenance treatment of unresectable locally advanced or metastatic HER2-positive breast cancer	Pertuzumab (Perjeta; R-1273) , Trastuzumab (Herceptin; RG-597) , Tucatinib (ONT-380)	Breast cancer	Breast Cancer	2023	View \| Download
Tucatinib in addition to trastuzumab and capecitabine for advanced breast cancer	Capecitabine (Xeloda) , Trastuzumab (Herceptin; RG-597) , Tucatinib (ONT-380)	Breast cancer	Breast Cancer	2020	View \| Download
Troriluzole for spinocerebellar ataxia	Troriluzole	Spinocerebellar ataxia	Genetic Disorders , Neurology	2024	View \| Download